[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598404":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":48,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients undergo collection of blood samples and have their medical records reviewed on study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-interventional study",[9],[20],{"name":21,"affiliation":22,"role":23},"Madeleine B. O'Keefe, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[31],{"facility":22,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-92.4699,44.02163,{"lat":42,"lon":41},[45,47],{"name":46,"role":27,"phone":10,"phoneExt":10,"email":29},"Clinical Trials",{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100598404","exploring-the-effect-of-calaspargase-pegol-on-the-coagulation-system-in-pediatric-acute-lymphoblastic-leukemia-all-patients-pilot-study-100598404",false,"NCT07071051","Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study","Inclusion Criteria:\n\n* Age 2-21.5 years\n* Confirmed diagnosis of acute lymphoblastic leukemia\u002Flymphoma\n* Planned treatment with Cal-PEG\n* Informed consent obtained from parents or guardians\n\nExclusion Criteria:\n\n* Pre-existing coagulation disorders\n* Known hypersensitivity to asparaginase products\n* Liver failure\n* Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)\n* Currently pregnant\n* Use of systemic blood thinner within 48 hours prior to study blood draw","ALL","2 Years","22 Years",{"count":60,"type":61},15,"ESTIMATED","OBSERVATIONAL","This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia\u002Flymphoma (ALL).",[65,66],"Childhood Acute Lymphoblastic Leukemia","Childhood Lymphoblastic Lymphoma","2026-02-11",{"date":69,"type":70},"2026-02-13","ACTUAL",{"date":72,"type":70},"2025-07-31",{"date":74,"type":61},"2026-12-31",{"name":5,"class":6},1]